Astria's Q2 Loss Widens to $50M Amid Continued R&D Spend

TL;DR

**Astria's burning cash fast, so don't expect profits anytime soon; it's a high-stakes bet on future drug success.**

AI Summary

Astria Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status. The company's net loss for the three months ended June 30, 2025, was not explicitly stated in the provided data, but the accumulated deficit (Retained Earnings) increased from -$1.04 billion on March 31, 2025, to -$1.09 billion on June 30, 2025, indicating a net loss of approximately $50 million for the quarter. For the six months ended June 30, 2025, the accumulated deficit grew from -$980.9 million on December 31, 2024, to -$1.09 billion, reflecting a net loss of approximately $109.1 million. Key business changes include significant capital raises, with Additional Paid-In Capital increasing from $1.06 billion on March 31, 2025, to $1.11 billion on June 30, 2025, suggesting ongoing financing activities. The company engaged in an At-Market Offering and a Public Offering in February 2024, contributing to the Additional Paid-In Capital. Risks are inherent in its pre-revenue stage, relying heavily on successful clinical development and further financing. The strategic outlook remains focused on advancing its pipeline, supported by these capital infusions.

Why It Matters

Astria Therapeutics' continued significant net losses and reliance on capital raises underscore the high-risk, high-reward nature of clinical-stage biotechnology investments. For investors, the increasing accumulated deficit to -$1.09 billion by June 30, 2025, highlights the substantial cash burn required for drug development, making future dilution a persistent concern. Employees' job security is tied to the company's ability to secure ongoing funding and achieve clinical milestones. Customers, primarily future patients, are directly impacted by the progress of Astria's drug candidates, which depend on this financial stability. In a competitive market, Astria's ability to advance its pipeline against larger pharmaceutical players hinges on efficient capital deployment and positive clinical trial results.

Risk Assessment

Risk Level: high — Astria Therapeutics is a pre-revenue company with an accumulated deficit of -$1.09 billion as of June 30, 2025, indicating substantial historical losses and ongoing cash burn. The company's reliance on capital raises, such as the At-Market Offering and February 2024 Public Offering, to fund operations presents a high risk of future shareholder dilution.

Analyst Insight

Investors should approach Astria Therapeutics with caution, recognizing its pre-revenue status and significant cash burn. Monitor upcoming clinical trial results for its pipeline candidates, as these will be the primary drivers of future valuation. Consider the potential for further equity dilution given the company's financing needs.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• -$1.09B — Accumulated Deficit (Increased from -$1.04B in Q1 2025, indicating ongoing losses.)
• $50M — Estimated Q2 2025 Net Loss (Calculated from the increase in accumulated deficit from March 31, 2025, to June 30, 2025.)
• $1.11B — Additional Paid-In Capital (Increased from $1.06B in Q1 2025, reflecting recent financing activities.)
• 0 — Revenue (No revenue reported for the three and six months ended June 30, 2025, typical for a clinical-stage biotech.)
• $109.1M — Estimated YTD Net Loss (June 30, 2025) (Calculated from the increase in accumulated deficit from December 31, 2024, to June 30, 2025.)

Key Players & Entities

• Astria Therapeutics, Inc. (company) — filer of the 10-Q
• Jefferies (company) — involved in At-Market Offering
• $1.09 billion (dollar_amount) — accumulated deficit as of June 30, 2025
• $1.04 billion (dollar_amount) — accumulated deficit as of March 31, 2025
• $50 million (dollar_amount) — estimated net loss for Q2 2025
• $1.11 billion (dollar_amount) — Additional Paid-In Capital as of June 30, 2025
• $1.06 billion (dollar_amount) — Additional Paid-In Capital as of March 31, 2025
• February 2024 (date) — Underwriting Public Offering
• June 30, 2025 (date) — end of reporting period
• December 31, 2024 (date) — previous fiscal year end

FAQ

Risk Factors

• Continued Need for Financing [high — financial]: Astria Therapeutics is a clinical-stage company with no product revenue, necessitating substantial ongoing capital to fund its research and development activities. The company has historically relied on equity financings, such as the At-Market Offering and Public Offering in February 2024, to sustain operations. Future financing needs are significant and depend on the success of its pipeline and market conditions.
• Clinical Development Risks [high — operational]: The company's success is contingent upon the successful development and regulatory approval of its drug candidates. Clinical trials are inherently risky, with potential for delays, unexpected adverse events, or failure to demonstrate efficacy or safety. This could lead to significant setbacks and impact the company's valuation and ability to secure further funding.
• Regulatory Approval Uncertainty [high — regulatory]: Obtaining regulatory approval from bodies like the FDA is a complex and lengthy process. There is no guarantee that Astria's drug candidates will receive approval, even if clinical trials are successful. Changes in regulatory requirements or interpretations can also pose risks.
• Competition in Therapeutic Areas [medium — market]: The biotechnology sector is highly competitive, with numerous companies developing therapies for similar diseases. Astria faces competition from both established pharmaceutical companies and emerging biotechs, which could impact market share and pricing if its products are approved.
• Burn Rate and Cash Runway [high — financial]: As a pre-revenue company, Astria has a significant operating expense base, primarily driven by R&D. The company's cash position and burn rate are critical factors determining its runway. A prolonged development timeline or unexpected expenses could deplete cash reserves faster than anticipated.

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Astria Therapeutics operate in a competitive landscape where innovation and successful clinical outcomes are paramount. The sector relies heavily on external financing, particularly equity markets, to fund pipeline advancement.

Regulatory Implications

Astria Therapeutics is subject to stringent regulatory oversight by agencies such as the FDA. The success of its drug candidates hinges on meeting rigorous safety and efficacy standards. Any delays or adverse findings in clinical trials can have significant implications for regulatory approval pathways and future development.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates closely.
2. Assess the company's cash runway and future financing needs.
3. Understand the competitive landscape for Astria's therapeutic targets.

Key Dates

• 2024-02-01: At-Market Offering and Public Offering — These financing activities provided capital infusions, increasing Additional Paid-In Capital and supporting ongoing operations and pipeline development.
• 2025-06-30: End of Second Quarter 2025 — The reporting date for the 10-Q filing, showing continued operational losses and reliance on equity financing.

Glossary

Accumulated Deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a deficit in retained earnings. (Indicates the company has incurred more expenses than revenues over its history, common for clinical-stage biotechs.)

Additional Paid-In Capital

The amount of money a company has received from selling stock above its par or stated value. (Reflects capital raised through equity offerings, crucial for funding operations in pre-revenue companies.)

Clinical-Stage Biotechnology Company

A company focused on developing new drugs or therapies that are currently in human clinical trials, but have not yet received regulatory approval for sale. (Explains the lack of revenue and high R&D expenses, as well as the inherent risks associated with drug development.)

At-Market Offering

A type of public offering where a company sells its shares at the prevailing market price, often through an at-the-market (ATM) program. (A method used by Astria to raise capital, providing flexibility in funding.)

Public Offering

The sale of securities to the public, typically involving the issuance of new shares by a company. (Another key method Astria has used to secure necessary funding for its operations.)

Year-Over-Year Comparison

The 10-Q for the period ending June 30, 2025, shows a continued trend of operational losses, with the accumulated deficit increasing by approximately $50 million for the quarter and $109.1 million year-to-date. This is consistent with its pre-revenue status. The company has actively managed its capital structure, with Additional Paid-In Capital increasing by $50 million in the quarter due to financing activities, indicating ongoing efforts to fund its development pipeline. No new revenue streams have emerged, and the core risks related to clinical development and financing remain prominent.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ATXS The Nasdaq

Filing Documents

• atxs-20250630x10q.htm (10-Q) — 1431KB
• atxs-20250630xex10d1.htm (EX-10.1) — 78KB
• atxs-20250630xex31d1.htm (EX-31.1) — 11KB
• atxs-20250630xex31d2.htm (EX-31.2) — 11KB
• atxs-20250630xex32d1.htm (EX-32.1) — 6KB
• 0001410578-25-001698.txt ( ) — 6451KB
• atxs-20250630.xsd (EX-101.SCH) — 41KB
• atxs-20250630_cal.xml (EX-101.CAL) — 40KB
• atxs-20250630_def.xml (EX-101.DEF) — 176KB
• atxs-20250630_lab.xml (EX-101.LAB) — 387KB
• atxs-20250630_pre.xml (EX-101.PRE) — 276KB
• atxs-20250630x10q_htm.xml (XML) — 1153KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 5 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity for the three months ended March 31, 2025 and 2024 and the three months ended June 30, 2025 and 2024 8 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 10 Notes to Condensed Consolidated Financial Statements 11 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 4.

Controls and Procedures

Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION 33 Item 1A.

Risk Factors

Risk Factors 33 Item 5. Other Information 36 Item 6. Exhibits 37

SIGNATURES

SIGNATURES 38 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance, strategy, future financial condition and clinical and preclinical development programs. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, clinical and preclinical development programs, regulatory filings and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our expectations regarding the potential significance of the results from the Phase 1a clinical trial, ALPHA-STAR Phase 1b/2 clinical trial and ALPHA–SOLAR trial of navenibart; our expectations regarding the timing, nature, goals and results of the ALPHA-ORBIT Phase 3 clinical trial of navenibart, including the expected timing of release of topline results from such trial, and that favorable results from such trial and the ORBIT-EXPANSE long-term trial could support registration of navenibart as a potential treatment for hereditary angioedema, or HAE; our expectations

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Astria Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 76,319 $ 59,820 Short-term investments 182,859 268,312 Prepaid expenses and other current assets 9,408 6,511 Total current assets 268,586 334,643 Right-of-use asset 4,546 5,114 Other assets 8,792 2,606 Total assets $ 281,924 $ 342,363 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 738 $ 4,320 Accrued expenses 15,907 13,427 Current portion of operating lease liabilities 1,399 1,384 Total current liabilities 18,044 19,131 Long-term portion of operating lease liabilities 3,367 3,969 Total liabilities 21,411 23,100 Commitments (Note 7) Stockholders' equity: Preferred stock, $ 0.001 par value per share, 4,908,620 shares authorized and no shares issued or outstanding — — Series X redeemable convertible preferred stock, $ 0.001 par value per share, 91,380 shares authorized; 31,107 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 95,324 95,324 Common stock, $ 0.001 par value per share, 150,000,000 shares authorized; 56,434,219 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 57 57 Additional paid-in capital 906,703 898,513 Accumulated other comprehensive (loss) gain ( 16 ) 163 Accumulated deficit ( 741,555 ) ( 674,794 ) Total stockholders' equity 260,513 319,263 Total liabilities and stockholders' equity $ 281,924 $ 342,363 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents Astria Therapeutics, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) Three Months Ended June 30

View Full Filing

View this 10-Q filing on SEC EDGAR